Drugs in Treatment of Developmental Dyslexia
An acute 2 day trial of methylphenidate (10 mg) and of meclizine (12.5 mg) and a 6 month crossover placebo-controlled chronic trial of meclizine (12.5 mg) in children with developmental dyslexia are reported from the University of Calgary, Alberta, Canada.
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pediatric Neurology Briefs Publishers
1988-12-01
|
| Series: | Pediatric Neurology Briefs |
| Subjects: | |
| Online Access: | https://www.pediatricneurologybriefs.com/articles/3582 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|